Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be...
-
- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at...
-
Patient enrollment and data generation remain on schedule with 13 patients having received CUE-101 to date and enrollment continues per protocol to identify a recommended Phase 2 doseDose-proportional...
-
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
-
CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
-
CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
-
Collaboration to Study Immuno-STAT Biologics on T Cell Immunological Synapse Formation Using the IL-2-Based CUE-100 Series CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc....
-
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
-
- Ongoing Phase 1 dose escalation and expansion study with CUE-101 as a monotherapy in post first-line recurrent/metastatic HNSCC patients to be amended to include combination of CUE-101 with standard...
-
Extended cash runway with $33.3 million from at-the-market equity offerings in Q4’19Focused and effective execution of clinical development of CUE-101 as a Phase 1 monotherapy dose escalation and...